Research company Hamlet Biopharma has initiated the clinical phase of its Phase 3 study of Alpha1H in patients with non-muscle-invasive bladder cancer. This is stated in a press release.Patients are being recruited and treated according to the study protocol, which has been approved by the European EMA and the US FDA. The study is being conducted at Motol Hospital in Prague.In parallel, Biopharma is preparing a separate clinical study at the University of Iowa for patients with severe, treatment-resistant carcinoma in situ.